Eric davis - TestsForge (TForge & TF) Expert Profile


Before making his career at TestsForge as a Software Developer, Eric Davis worked at IBM, Cisco Systems, and Juniper Networks. He has performed the tasks required for the job roles of Technical Staff Member, R&D Staff Member, and Software Engineer. These skills were initially developed at the University of California at Berkeley, where Eric Davis obtained his education. Eric Davis considers the following among his technical level of expertise: Cloud services, Web application testing, mobile applications development, and HTML. His research is focused mostly on the following certification exams: 220-603 Remote Support Tech designation pathway, 3102 Avaya Aura Session Manager and System Manager Implementation and Maintenance, E22-220 Symmetrix Mainframe Business Continuity, 640-447 CVOICE, E20-594 Backup Recovery - Avamar Specialist Exam for Implementation Engineers, JN0-633 Security, Professional (JNCIP-SEC), HP0-083 OpenVMS Network Administration, 650-157 Cisco IronPort Security Instructor - Email Security (ISIES), HP2-E35 Administering HP Converged Infrastructure Solutions, 350-018 CCIE Security written, TMPTE TMap NEXT® Test Engineer, HP2-K30 Technical Introduction to the HP Storage SMB Portfolio, HP0-758 HP ProCurve Mobility, SK0-003 CompTIA Server+. Eric Davis also creates the website of trlusa. Tanabe Research Laboratories, part of Mitsubishi Tanabe Pharmaceutical Corporation, is in the business of creating biological drug candidates for use in therapy, particularly in the treatment of autoimmune diseases. This is a new focus, having started in 2010 minimizing small molecule drug discovery and instead increasing efforts in biologics. This has worked well and has brought the company to new heights, its best since its inception in 1990. Eric Davis’s website not only lists the company’s board of directors and management team, but also the research itself, and the entire management team leading the way on biologics research. Students interested in the science field can also inquire about careers or review the latest news on lab results. Test results coming back in 2013 revealed some amazing discoveries, and the future looks brighter, as the institution is already establishing collaborative relationships with other academic research organizations to double their efforts in finding new developments.



1. About the webpage pr/20121017.html: This press release page by Eric Davis mentions the collaboration and license agreement with another company called Covagen. This will be for the development of bispecific FynomAbs and funding activities are explained. This report provides information on both companies and on the anticipated project. ... Tanabe Research Laboratories U.S.A. Inc. (TRL) and its parent company Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) have entered into a strategic research collaboration and license agreement...

 

2. About the webpage research.html: Eric Davis’s research page includes information tidbits on research assignments and future efforts in immunological and molecular biology. This page mentions the role of the Mitsubishi Tanabe Pharmaceutical Corporation as well as the “New TRL” development of 2010. As of now, all efforts are being directed towards antibody and antibody related research. ... TRL is an independent subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation (MTPC) whose role is to discover and develop potential biological drug candidates for therapy in autoimmune diseases. ...

 

3. About the webpage board_of_directors.html: The board of directors for Tanabe Research Laboratories is listed on this page, including three instrumental members of the company in Ryoichi Ando, Naoki Sakurai, and Eisuke Kume. All members of the board have PhDs and are experienced in their field. ... Dr. Ando is currently General Manager of the Research Coordination & Administration Department of MTPC. He joined Mitsubishi Chemical Industries, Ltd., one of preceding companies of MTPC, in 1983. ...

 

4. About the webpage management_team.html: Tanabe Research Laboratories’ entire team is highlighted on the Management page. The Chief Executive Officer and President Naoki Sakurai, as well as the Vice President and Chief Scientific Officer are listed, in addition to two other vice presidents. The board of directors follows the management listings. ... Naoki Sakurai, Ph.D. has served as President & CEO of Tanabe Research Laboratories (TRL) since June 2011. Dr. Sakurai has held numerous positions with increasing responsibilities...

 

5. About the webpage careers.html: Are you interested in a promising career with one of the top biology companies in the nation? This Careers page lists open positions for candidates as well as the requirements in education and experience. The management team for Tanabe Research Laboratories is also profiled. ... TRL is a research organization that has transformed itself to refocus its discovery efforts on biological agents for the treatment of autoimmune diseases....

 

6. About the webpage pr/20111004.html: This press release page by Eric Davis announces a new partnership for Tanabe Research Labs in X-BODY. Collaborative plans include identifying therapeutic target epitopes and creating antibodies for therapeutic targets. The press release from 2011 provides information on X-BODY’s history as well as Tanabe Research Lab’s own experience. ... WALTHAM, Mass., October 4, 2011 /Business Wire/ -- X-BODY, Inc., a developer of monoclonal antibody therapeutics, today announced a partnership with Tanabe Research Laboratories ...

 

7. About the webpage pr/pr_news.html: This press release page focuses on a new development in the Tanabe Research Laboratories company. The first Bispecific FynomAb for Preclinical Development and Exercise was announced on November of 2013. There is also an option for a Second Bispecific FynomAb Program. This page previews the development along with company information. ... Tanabe Research Laboratories and Mitsubishi Tanabe Pharma Nominate First Bispecific FynomAb® for Preclinical Development and Exercise an Option for a Second Bispecific FynomAb Program ...

 

8. About the webpage pr/20101213.html: This press release page announces Tanabe Research Laboratories partnership with Anaphore, with the intent of developing Novel Protein Pharmaceuticals. This biological research and protein therapy will be used to treat autoimmune disorders. Eric Davis’s press release explains the science of the therapy along with company information for both participants. ... San Diego, CA - (December 13th, 2010) - Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc....

 

The trademarks of TForge and TF certifications training are owned, registered and/or licensed by TestsForge, Inc.

©2014 Testsforge.com. All rights reserved.Site Map